Fortress Biotech, Inc. (FBIO): Gross Profit
$42.34M
Year ended 2025-12-31
$44.91M
Trailing 12 months to 2026-06-30
| Period ended | Gross Profit | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $42.34M | +15.1% | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | $36.80M | -40.3% | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | $61.62M | n/c | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $44.97M | +22.5% | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | $36.71M | +18.4% | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $31.00M | +18.8% | 2022-03-28, From 2020-01-01 |
| 2019-12-31 | $26.10M | +25.7% | 2021-04-09, From 2019-01-01 |
| 2018-12-31 | $20.76M | +52.8% | 2020-03-16, From 2018-01-01 |
| 2017-12-31 | $13.59M | n/a | 2019-03-18, From 2017-01-01 |
Gross Profit at similar companies
| Company | Year ended | Gross Profit | Change YoY |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $42.34M | +15.1% |
| Nuvation Bio Inc. (NUVB) | 2024-12-31 | $795.0K | n/a |
| Journey Medical Corp (DERM) | 2025-12-31 | $40.31M | +17.7% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $11.70M | -33.1% |
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | $36.82M | -19.7% |
| Nektar Therapeutics (NKTR) | 2024-12-31 | $67.74M | +20.2% |
| Integrated Biopharma Inc (INBP) | 2025-06-30 | $5.56M | +43.2% |
| Agios Pharmaceuticals, Inc. (AGIO) | 2025-12-31 | $47.68M | +47.5% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $45.38M | -21.9% |
Compare FBIO, NUVB, DERM, RMTI side by side · Screen every company in Pharmaceutical Preparations ↗